Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Commissioner Short List Candidates Have Industry Connections

Executive Summary

The three top candidates on the Bush Administration list to head FDA have significant connections to the drug and biotech industries:
Advertisement

Related Content

“Regulatory Predictability” Is Key Barrier To Orphan Drug Development, Social Security Head Astrue Says
“Regulatory Predictability” Is Key Barrier To Orphan Drug Development, Social Security Head Astrue Says
FDA Urged To Improve “Predictability” For Orphan Drugs By Social Security Head Astrue
"Regulatory Predictability" Is Key Barrier To Orphan Drug Development, Social Security Head Astrue Says
"Regulatory Predictability" Is Key Barrier To Orphan Drug Development, Social Security Head Astrue Says
Sen. Kennedy Warns Against Picking FDA Commissioner From Industry
Merck R&D Labs Heir-Apparent Kim To Head Basic Research, Clinical Science
Merck R&D Labs Heir-Apparent Kim To Head Basic Research, Clinical Science
Advertisement
UsernamePublicRestriction

Register

PS038175

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel